$MBX round trip post MBX 2109 phase 2 readout. Now 25% below the offering pricing in this biotech bull market.

🧠

Buffalo bills Snaking I agree this tipping point analysis is exactly like $avxl. The $prax claim of p<0.0001 seems at odds with the TP value which requires missing values imputed to be better than placebo response. Plus there were lots of imputed values (35%).

Buffalo bills Snaking as for that $prax footnote that suggests a TP >1/2 a SD is "robust"... I don't think that is exactly what they said. (meaningful 🚫 plausible)

Who wins the CNPV of ketamine? It only costs $200-300 to buy 1kg ketamine from other countries.

90% is a small fraction 🤷‍♂️

$PRAX (1) Biotwit brainiacs - anyone else thinking this is a big deal or am I just reading wwwaaayyyy too much into this? Ok so they did tipping point in the mITT population to assess robustness. Fine, great. Results look decent

Maybe the next $ABVX... is $ABVX -- Sheep

🤔 - 40% discontinue beta blockers and anti-convulsants within 2 years - 35-38% discontinue ulixacaltamide within 0.23 years

topical and vague Rx commentary "I will show you the data if you agree to buy my Vepdeg"